EGFR and gastric cancer: Taraxasterol (TAX) (Chen, et al., 2020), with strong antitumor activity, was found to have five common targets with gastric cancer, namely, EGFR, MMP2, AKT1, BRAF, and FGFR2, through network pharmacology methods and animal experiments.